Year All2024202320222021202020192018201720162015201420132012201120102007 09.15.21 Syndax Appoints Martin H. Huber, M.D., to its Board of Directors WALTHAM, Mass. , Sept. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the expansion of its Board of Directors to nine members Read More 09.02.21 Syndax Announces Participation at Three Upcoming Investor Conferences WALTHAM, Mass. , Sept. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in Read More 08.09.21 Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update - Intermediate doses selected for Phase 2 portion of AUGMENT-101 trial of SNDX-5613 in patients with genetically-defined acute leukemias; updated results from Phase 1 portion anticipated in 4Q21 - - Syndax initiating frontline combination of SNDX-5613 with venetoclax and azacitidine in the Beat® Read More 08.02.21 Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021 WALTHAM, Mass. , Aug. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2021 financial Read More 06.28.21 SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias WALTHAM, Mass. , June 28, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Read More 06.03.21 Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference WALTHAM, Mass. , June 3, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Read More 05.13.21 Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit WALTHAM, Mass. , May 13, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Read More 05.11.21 Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update - Today announced two of the prior responders from ongoing Phase 1 portion of AUGMENT-101 trial of SNDX-5613 achieved full count recovery bringing CR/CRh rate up to 23% - - Company on track to initiate pivotal Phase 2 portion of AUGMENT-101 trial in 2Q21 - - Enrollment of 23 cGVHD patients in Phase Read More 05.04.21 Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021 WALTHAM, Mass. , May 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2021 financial Read More 04.20.21 Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients with Genetically-Defined Acute Leukemias - 48% overall response rate in patients with MLLr or NPM1c; 67% of responders achieved minimal residual disease-negative status - - Doses identified for advancement into Phase 2 - - Company on track to initiate pivotal Phase 2 portion of trial in 2Q21- - Company to host conference call and webcast Read More 04.15.21 Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias - Event to be webcast live on Tuesday, April 20, 2021 at 8:00 a.m. ET - WALTHAM, Mass. , April 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, Read More 04.08.21 Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis WALTHAM, Mass. , April 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Read More
09.15.21 Syndax Appoints Martin H. Huber, M.D., to its Board of Directors WALTHAM, Mass. , Sept. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the expansion of its Board of Directors to nine members Read More
09.02.21 Syndax Announces Participation at Three Upcoming Investor Conferences WALTHAM, Mass. , Sept. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in Read More
08.09.21 Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update - Intermediate doses selected for Phase 2 portion of AUGMENT-101 trial of SNDX-5613 in patients with genetically-defined acute leukemias; updated results from Phase 1 portion anticipated in 4Q21 - - Syndax initiating frontline combination of SNDX-5613 with venetoclax and azacitidine in the Beat® Read More
08.02.21 Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021 WALTHAM, Mass. , Aug. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2021 financial Read More
06.28.21 SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias WALTHAM, Mass. , June 28, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Read More
06.03.21 Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference WALTHAM, Mass. , June 3, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Read More
05.13.21 Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit WALTHAM, Mass. , May 13, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Read More
05.11.21 Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update - Today announced two of the prior responders from ongoing Phase 1 portion of AUGMENT-101 trial of SNDX-5613 achieved full count recovery bringing CR/CRh rate up to 23% - - Company on track to initiate pivotal Phase 2 portion of AUGMENT-101 trial in 2Q21 - - Enrollment of 23 cGVHD patients in Phase Read More
05.04.21 Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021 WALTHAM, Mass. , May 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2021 financial Read More
04.20.21 Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients with Genetically-Defined Acute Leukemias - 48% overall response rate in patients with MLLr or NPM1c; 67% of responders achieved minimal residual disease-negative status - - Doses identified for advancement into Phase 2 - - Company on track to initiate pivotal Phase 2 portion of trial in 2Q21- - Company to host conference call and webcast Read More
04.15.21 Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias - Event to be webcast live on Tuesday, April 20, 2021 at 8:00 a.m. ET - WALTHAM, Mass. , April 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, Read More
04.08.21 Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis WALTHAM, Mass. , April 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Read More